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Introduction
A paradox of neurodegenerative diseases is that they
are easy to diagnose as a result of abnormal behavior,
but are hard to treat. Alzheimer’s disease (AD) is an
example of such a disease. A typical symptom of AD 
in its initial phase is episodic or severe memory loss/
impairment, which can be easily characterized. However,
AD remains an incurable disorder to this day and senile
dementia caused by AD affects more than 20 million
people worldwide [1,2]. With the dramatic increase in
the aged population (i.e. the number of people over
60 years of age is expected to triple by 2050 in China)
[3], AD is considered a crucial global health issue, 
and finding a suitable treatment for AD has become 
a challenge for modern medicine.
The first case of AD was described by Alois Alzheimer
on November 3, 1906, at the 37th meeting of the Society
of Southwest German Psychiatrists in Tübingen, Germany
[2]. The brain anatomy of patients with AD has helped
identify two hallmarks that define the neuropathologi-
cal characteristics of AD, namely, the neuritic plaques
and the neurofibrillary tangles. In the 1960s, abnor-
mal amyloid-like filaments in the plaques and tangles
were observed under the electron microscope [4,5]. It
has also been established that the localization of plaques
and tangles are different: plaque filaments are deposited
extracellularly, while most of the tangle filaments are
present intracellularly, deposited in nerve cell bodies
as well as in the neuropil in neuritis. The presence of
these two unique deposits has greatly helped in char-
acterizing AD [6]. In addition, plaques appear as fila-
ments 10 nm in diameter under electron microscope,
exhibiting a cross-β structure as well as characteristic
dye-binding properties [2]. The next breakthrough to
clarify the mechanism of AD took another 20 years,
and revealed that the major molecular compositions
of the plaques and tangles were different: amyloid-β
ALZHEIMER’S DISEASE: AGING, INSOMNIA AND
EPIGENETICS
Tzong Yuan Wu1,2,3*, Chih-Ping Chen4,5, Tzyy-Rong Jinn6
1Department of Bioscience Technology, 2Center for Nanotechnology, and 3R&D Center of Membrane Technology, 
Chung Yuan Christian University, Chung Li, Departments of 4Obstetrics and Gynecology and 
5Medical Research, Mackay Memory Hospital, Taipei, and 6Graduate Institute of 
Chinese Medical Science, China Medical University, Taichung, Taiwan.
SUMMARY
Alzheimer’s disease (AD) is the most common form of dementia. Severe memory loss, confusion, and impaired
cognitive abilities characterize AD. It was only a century after Alzheimer’s discovery that scientists were able to
shed light on the mystery of its cause, but AD has also become a globally important health issue and the treat-
ment of AD is a challenge for modern medicine. At present, there are five drugs approved in the United States
for the treatment of AD, namely, donepezil, galantamine, rivastigmine, and tacrine (which are all cholinesterase
inhibitors); and memantine (which is a glutamate receptor antagonist). However, these drugs show only modest
effects on AD patients. Thus, new investigations are necessary for pharmacological development in AD. This brief
review focuses on new studies that demonstrate the link between epigenetics and AD, and explores the possibility
that insomnia may be one factor that effects AD. [Taiwan J Obstet Gynecol 2010;49(4):468–472]
Key Words: Alzheimer’s disease, epigenetics, insomnia, orexin
*Correspondence to: Professor Tzong-Yuan Wu,
Department of Bioscience Technology, Chung Yuan
Christian University, Chung-Li 32023, Taiwan.
E-mail: tywu@cycu.edu.tw
Accepted: October 6, 2010
Taiwan J Obstet Gynecol • December 2010 • Vol 49 • No 4 469
Alzheimer’s Disease: Aging, Insomnia and Epigenetics
(Aβ) peptide is the major plaque component [7–10],
while hyperphosphorylated tau protein is the major
tangle component [11–15]. The 40–42-amino acid Aβ
peptide can be derived from the sequential cleavage of
the amyloid precursor protein (APP), a type 1 trans-
membrane protein, by two proteases, β- and γ-secretase
[1,2]. Tau is a protein involved in microtubule assembly
and stabilization. There are six tau isoforms produced
from a single gene through alternative RNA splicing in
the human brain [16]. Consistent with these biochem-
ical studies of the abnormal filaments in AD, transgenic
mouse models of AD that target both the APP and tau
genes also confirm their genetic pathogenicity. Thus, the
expression of APP and tau proteins became the major
targets of drugs currently being tested for AD [1]. An
understanding of how to regulate the expression of APP
and tau in the brain will be critical to treatments for AD.
Because AD is a complicated neurodegenerative
disease to cure, most AD patients also receive antipsy-
chotic or antidepressant drugs aside from the actual
AD drug to manage neuropsychiatric and behavioral
symptoms, or take over-the-counter medications with
uncertain therapeutic value such as ginkgo biloba and
vitamins C and E [17–22]. Recently, dimebon failed in
a Phase III clinical trial for AD, although this antihista-
mine drug was once thought to be the “dark-horse” of
Alzheimer’s medications [23]. At present, there are five
drugs used in the treatment of AD: (1) the cholinesterase
inhibitors: donepezil, galantamine, rivastigmine and
tacrine; and (2) the glutamate receptor antagonist:
memantine. All have been approved in the United States
for treatment of AD [17,22], although tacrine is now
rarely used because of hepatotoxicity. Cholinesterase
inhibitors can combat the impairment of cholinergic
neurons in AD patients by slowing the degradation of
acetylcholine released from synapses during neuro-
transmission. Memantine prevents the overstimulation
of the N-methyl-D-aspartate (NMDA) subtype of glu-
tamate receptors to prevent calcium-induced excito-
toxicity, which may contribute to the pathogenesis of AD
and other neurodegenerative conditions [24]. Recent
studies have suggested that memantine, an analogue of
amantadine that inhibits the internal ribosome entry
site (IRES) of picornavirus-mediated translation [25],
can also prevent expression of APP and tau via the
inhibition of a translation initiation mechanism that 
is mediated by the IRES [26]. In clinical trials, both
cholinesterase inhibitors and memantine have proven
beneficial to AD patients [17–21]. However, these drugs
only show modest effects on AD patients’ cognitive test
scores, behavioral measures, and functional outcomes.
In this review, we describe some recent interesting find-
ings that point to new concepts about AD.
AD and Insomnia
Sleep is a complex physiological state, and its ultimate
function remains to be elucidated. A characteristic of
sleep is the sleep-wake cycle. One interesting study indi-
cated that Aβ levels of brain interstitial fluid (ISF), when
analyzed by in vivo microdialysis, were significantly in-
creased while awake as compared with the sleeping
state both in C57BL6 mice and human APP transgenic
mice, Tg2576 [27]. Cerebrospinal fluid (CSF) levels of
Aβ also fluctuate during the sleep-wake cycle in humans;
mean peak CSF Aβ levels from 7 pm to 9 pm were found
to be 27.6% higher than mean trough CSF Aβ levels
from 9 am to 11 am [27]. These results raise interest-
ing questions: (1) Does insomnia have a link with AD?
(2) Do factors that are involved in sleep contribute to
the pathogenesis of AD? Since it was established that
the neuropeptide orexin can regulate wakefulness and
can be strongly implicated in sleeping and waking dis-
orders [28], it would be fascinating to know whether
the concentration fluctuation of orexin can affect the
concentration of Aβ in the brain. Orexin is released from
hypothalamic neurons and fluctuates diurnally similar to
that of ISF Aβ [29]. The function of orexin is mediated
through orexin receptors. The orexin family (orexin-A
and orexin-B) has two receptor subtypes: orexin recep-
tor 1 and orexin receptor 2 [30]. Interestingly, when a
dual orexin receptor antagonist, almorexant, was infused
intracerebroventricularly (icv) during in vivo microdialysis
for an ISF Aβ experiment, Kang et al discovered that the
ISF Aβ levels were suppressed and the natural diurnal
variation of Aβ was also abolished [27]. Furthermore,
they also revealed that ISF Aβ levels were significantly
increased upon icv infusion of orexin-A (1.5 pmol/hr, 
a dose that could induce wakefulness in rodents). The
physiological function of APP is not well established,
although some reports indicated that APP proteins were
involved in regulation of NMDA receptors [31,32].
These results implied that Aβ might be involved in the
physiological regulation of sleep. More importantly,
these findings suggested that sleep disturbances might
correlate with the pathogenesis of AD. Kang et al also
demonstrated significantly greater Aβ plaque deposi-
tion in multiple sub-regions of the cortex when chronic
sleep restriction was implemented 20 hours daily in APP
transgenic mice (APPswe/PS1dE9 genotype) for 21 days
[27]. Consistent with this remarkable observation was
the fact that systemic treatment with almorexant once
daily for 8 weeks could significantly decrease Aβ plaque
formation in aged APP transgenic mice. Hence these data
offered a new concept about how sleep and the opti-
mization of sleep time could possibly prevent aggre-
gation of Aβ and slow the progression of AD. Further
study, however, is needed to confirm the hypothesis that
almorexant, developed by a pharmaceutical company
for the treatment of primary insomnia, is a potential
drug that can inhibit the deposition of Aβ plaque and
thus prevent AD pathogenesis.
AD and Epigenetic Change with Aging
A striking feature of AD is that most cases are sporadic,
with dominantly inherited forms accounting for less
than 1% of the total [2]. Although some genes associ-
ated with early-onset AD have already been identified,
genetic causes cannot explain an overwhelming pro-
portion of diagnosed AD cases. Environment or nur-
ture, like the aforementioned insomnia, may also be
critical for the pathogenesis of AD. Thus, the question
is how environmental factors rather than the genetic
factors correlate with AD. Besides, recent studies con-
cerning the chemical modification of chromatin may
have highlighted a new direction in the study of the eti-
ology and drug development of AD. These studies sug-
gested that DNA methylation and histone acetylation
and methylation, collectively known as epigenetics, in
the neuron may change with the aging process and can
probably explain the observed anomalies in AD, as
aberrant epigenetic patterns may be acquired during
developmental stages [33].
Epigenetic mechanisms of gene regulation have long
been familiar to developmental and cancer biology.
These molecular mechanisms alter the activity of genes
without changing their DNA sequence. Acetylation of
histones tends to enhance gene expression, whereas
methylation of histones and DNA tends to suppress
gene expression [34]. Although during the early 1990s
a study from one post-mortem brain sample of an
unaffected patient suggested that the APP promoter 
is always unmethylated in the brain and hence may 
not be regulated by DNA methylation in the brain of
healthy individuals [35], this study did not compare
statistical relevant quantities of samples; nor did the
study reveal whether DNA methylation of the investi-
gated sites was present in AD patients [33]. In the late
1990s, several studies demonstrated that abnormali-
ties in DNA methylation were involved in brain disor-
ders that caused intellectual impairment, including
Angelman syndrome and Rett syndrome [33]. More
importantly, epigenetic studies in neurons also found
that epigenetic mechanisms played an important role
in learning and memory and could help to explain why
memory declined with age [36], while also highlight-
ing a new drug target for AD. One study found that
training mice to associate a certain location with a
mild electric shock could reduce DNA methylation 
on the brain-derived neurotrophic factor (bndf) gene 
in the hippocampus. Demethylation of the bndf gene
boosted its activity and could promote new synaptic
connections between neurons, as well as allowing more
efficient memory retention [37]. Furthermore, infusions
of a DNA methyltransferase inhibitor, zebularine, sig-
nificantly induced bdnf DNA demethylation and was
sufficient to increase mRNA levels of bdnf in the hip-
pocampus [37]. Consistent with this finding was the
discovery that when long-term memory formation was
blocked by the NMDA receptor use-dependent antag-
onist MK801, bdnf DNA methylation as well as bdnf gene
expression was altered in the hippocampus, leading to
a deficiency in memory formation [37]. These results
suggested that epigenetic modification of the bdnf gene
may be a pivotal mechanism for memory consolidation.
This not only demonstrated how epigenetics affected
the formation and maintenance of memory, but also
implied that epigenetic modification of chromatin in
neurons might be the molecular basis for memory
decline experienced during aging and provides a new
clue in finding drugs that can treat AD.
Recently, an interesting study found that age-
dependent memory impairment was associated with
altered histone acetylation in mice. Peleg et al [38]
employed quantitative immunoblot analysis (using fluo-
rescent secondary antibodies), high-density oligonu-
cleotide microarray, quantitative real time polymerase
chain reaction, chromatin-immunoprecipitation (ChIP)
and ChIP-sequencing to investigate the chromatin remod-
eling that is associated with age and fear conditioning,
a commonly used model for hippocampus-dependent
associative learning in mice. First, they subjected 3-, 8-,
and 16-month-old C57BL/6 mice (mean life span about
26–28 months) to contextual fear conditioning and
found that 16-month-old mice exhibited impaired asso-
ciative learning. They also showed that these 16-month-
old mice, but not 3-month-old mice, failed to upregulate
histone H4 acetylation on lysine residues (K) 12 (H4K12)
specifically, although the levels and activity of his-
tone acetyltransferases (HATs) and histone deacetylases
(HDACs) were similar in 3- and 16-month-old mice
[38]. Importantly, this deregulated H4K12 acetylation in
aged mice correlated with the loss of almost all memory-
associated hippocampal transcriptome in 3-month-old
mice [38]. More specifically, the transcriptional regu-
lation of an actin regulatory protein, Form 2, which is
necessary for normal memory formation, was disrupted
by the deregulated H4K12 acetylation upon aging. Hence
this study illustrated that learning and memory could
be recovered through the epigenetic remodeling of
chromatin. Consistent with these findings, Fisher et al
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demonstrated that sodium butyrate, a drug that inhibits
HDACs and promotes histone acetylation, improved
learning and memory in CK-p25 Tg mice, a mouse model
of AD [39]. Thus, drugs that either enhance histone
acetylation through HATs or inhibit histone deacetyla-
tion through HDACs may act as candidates for treating
AD and other neurodegenerative diseases that impair
learning and memory.
Conclusion
Since a small group of psychiatrists used the silver stain-
ing method developed by Max Bielschowsky in 1902 to
describe abnormal neuritic plaques and neurofibrillary
tangles in the brain of AD patients [2], the treatment
of this neurodegenerative disease has been a challenge
to modern medicine. However, advances in histology
and protein chemistry in the 1960s has since allowed
identification of the protein composition of the deposits
found in abnormal neuritic plaques and neurofibrillary
tangles; that is, the Aβ and tau proteins opened the first
window to this therapeutic pursuit. When the enzymes
that produce Aβ were finally discovered in the 1990s,
inhibitors of secretases took the limelight as drugs
which could conquer AD. Besides the “enzyme hunter”,
progress in receptor biochemistry and neuroscience
has also led to the proposal of certain drugs which
could be beneficial in AD. However, these drugs only
showed modest effects on AD patients. It was only
after the development of genetics and molecular biol-
ogy studies on AD that mutations in the APP gene as
well as inheritance of the ε4 allele of apolipoprotein E
were recognized as contributory factors to the patho-
genesis of AD. In spite of this, most cases of AD are
sporadic, with dominantly inherited forms accounting
for less than 1% of AD patients. Thus, both environ-
mental factors and epigenetic changes may present a
critical issue for the treatment of AD. These specula-
tions are also consistent with the characteristics of AD,
that is, the long pre-symptomatic phase of AD. New
findings that epigenetic change can characterize the
mouse model of AD and that optimization of sleep
time could potentially slow the development of AD
point to new avenues in the search for a cure for AD.
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